The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
Background Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting...
Uloženo v:
| Vydáno v: | Breast cancer research : BCR Ročník 21; číslo 1; s. 47 - 17 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
03.04.2019
Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1465-542X, 1465-5411, 1465-542X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA
MIR2052HG
associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Our goal was to further elucidate MIR2052HG’s mechanism of action.
Methods
RNA-binding protein immunoprecipitation assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate that lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the
LMTK3
gene locus was mapped using chromatin immunoprecipitation assays. The co-localization of MIR2052HG RNA and the
LMTK3
gene locus was determined using RNA-DNA dual fluorescent in situ hybridization. Single-nucleotide polymorphisms (SNP) effects were evaluated using a panel of human lymphoblastoid cell lines.
Results
MIR2052HG depletion in breast cancer cells results in a decrease in LMTK3 expression and cell growth. Mechanistically, MIR2052HG interacts with EGR1 and facilitates its recruitment to the LMTK3 promoter. LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway. MIR2052HG regulated LMTK3 in a SNP- and aromatase inhibitor-dependent fashion: the variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. Finally, LMTK3 overexpression abolished the effect of MIR2052HG on PKC activity and ERα levels.
Conclusions
Our findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer. |
|---|---|
| AbstractList | Background Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Our goal was to further elucidate MIR2052HG’s mechanism of action. Methods RNA-binding protein immunoprecipitation assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate that lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the LMTK3 gene locus was mapped using chromatin immunoprecipitation assays. The co-localization of MIR2052HG RNA and the LMTK3 gene locus was determined using RNA-DNA dual fluorescent in situ hybridization. Single-nucleotide polymorphisms (SNP) effects were evaluated using a panel of human lymphoblastoid cell lines. Results MIR2052HG depletion in breast cancer cells results in a decrease in LMTK3 expression and cell growth. Mechanistically, MIR2052HG interacts with EGR1 and facilitates its recruitment to the LMTK3 promoter. LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway. MIR2052HG regulated LMTK3 in a SNP- and aromatase inhibitor-dependent fashion: the variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. Finally, LMTK3 overexpression abolished the effect of MIR2052HG on PKC activity and ERα levels. Conclusions Our findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer. Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Our goal was to further elucidate MIR2052HG's mechanism of action.BACKGROUNDOur previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Our goal was to further elucidate MIR2052HG's mechanism of action.RNA-binding protein immunoprecipitation assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate that lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the LMTK3 gene locus was mapped using chromatin immunoprecipitation assays. The co-localization of MIR2052HG RNA and the LMTK3 gene locus was determined using RNA-DNA dual fluorescent in situ hybridization. Single-nucleotide polymorphisms (SNP) effects were evaluated using a panel of human lymphoblastoid cell lines.METHODSRNA-binding protein immunoprecipitation assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate that lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the LMTK3 gene locus was mapped using chromatin immunoprecipitation assays. The co-localization of MIR2052HG RNA and the LMTK3 gene locus was determined using RNA-DNA dual fluorescent in situ hybridization. Single-nucleotide polymorphisms (SNP) effects were evaluated using a panel of human lymphoblastoid cell lines.MIR2052HG depletion in breast cancer cells results in a decrease in LMTK3 expression and cell growth. Mechanistically, MIR2052HG interacts with EGR1 and facilitates its recruitment to the LMTK3 promoter. LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway. MIR2052HG regulated LMTK3 in a SNP- and aromatase inhibitor-dependent fashion: the variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. Finally, LMTK3 overexpression abolished the effect of MIR2052HG on PKC activity and ERα levels.RESULTSMIR2052HG depletion in breast cancer cells results in a decrease in LMTK3 expression and cell growth. Mechanistically, MIR2052HG interacts with EGR1 and facilitates its recruitment to the LMTK3 promoter. LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway. MIR2052HG regulated LMTK3 in a SNP- and aromatase inhibitor-dependent fashion: the variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. Finally, LMTK3 overexpression abolished the effect of MIR2052HG on PKC activity and ERα levels.Our findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer.CONCLUSIONSOur findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer. Background Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Our goal was to further elucidate MIR2052HG’s mechanism of action. Methods RNA-binding protein immunoprecipitation assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate that lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the LMTK3 gene locus was mapped using chromatin immunoprecipitation assays. The co-localization of MIR2052HG RNA and the LMTK3 gene locus was determined using RNA-DNA dual fluorescent in situ hybridization. Single-nucleotide polymorphisms (SNP) effects were evaluated using a panel of human lymphoblastoid cell lines. Results MIR2052HG depletion in breast cancer cells results in a decrease in LMTK3 expression and cell growth. Mechanistically, MIR2052HG interacts with EGR1 and facilitates its recruitment to the LMTK3 promoter. LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway. MIR2052HG regulated LMTK3 in a SNP- and aromatase inhibitor-dependent fashion: the variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. Finally, LMTK3 overexpression abolished the effect of MIR2052HG on PKC activity and ERα levels. Conclusions Our findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer. Abstract Background Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Our goal was to further elucidate MIR2052HG’s mechanism of action. Methods RNA-binding protein immunoprecipitation assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate that lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the LMTK3 gene locus was mapped using chromatin immunoprecipitation assays. The co-localization of MIR2052HG RNA and the LMTK3 gene locus was determined using RNA-DNA dual fluorescent in situ hybridization. Single-nucleotide polymorphisms (SNP) effects were evaluated using a panel of human lymphoblastoid cell lines. Results MIR2052HG depletion in breast cancer cells results in a decrease in LMTK3 expression and cell growth. Mechanistically, MIR2052HG interacts with EGR1 and facilitates its recruitment to the LMTK3 promoter. LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway. MIR2052HG regulated LMTK3 in a SNP- and aromatase inhibitor-dependent fashion: the variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. Finally, LMTK3 overexpression abolished the effect of MIR2052HG on PKC activity and ERα levels. Conclusions Our findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer. Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Our goal was to further elucidate MIR2052HG's mechanism of action. RNA-binding protein immunoprecipitation assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate that lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the LMTK3 gene locus was mapped using chromatin immunoprecipitation assays. The co-localization of MIR2052HG RNA and the LMTK3 gene locus was determined using RNA-DNA dual fluorescent in situ hybridization. Single-nucleotide polymorphisms (SNP) effects were evaluated using a panel of human lymphoblastoid cell lines. MIR2052HG depletion in breast cancer cells results in a decrease in LMTK3 expression and cell growth. Mechanistically, MIR2052HG interacts with EGR1 and facilitates its recruitment to the LMTK3 promoter. LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway. MIR2052HG regulated LMTK3 in a SNP- and aromatase inhibitor-dependent fashion: the variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. Finally, LMTK3 overexpression abolished the effect of MIR2052HG on PKC activity and ERα levels. Our findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer. |
| ArticleNumber | 47 |
| Author | Kubo, Michiaki Goetz, Matthew P. Cairns, Junmei Shepherd, Lois E. Kalari, Krishna R. Weinshilboum, Richard M. Wang, Liewei Ingle, James N. |
| Author_xml | – sequence: 1 givenname: Junmei surname: Cairns fullname: Cairns, Junmei organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 2 givenname: James N. surname: Ingle fullname: Ingle, James N. organization: Division of Medical Oncology, Mayo Clinic – sequence: 3 givenname: Krishna R. surname: Kalari fullname: Kalari, Krishna R. organization: Department of Health Sciences Research, Mayo Clinic – sequence: 4 givenname: Lois E. surname: Shepherd fullname: Shepherd, Lois E. organization: NCIC Clinical Trials Group, Kingston – sequence: 5 givenname: Michiaki surname: Kubo fullname: Kubo, Michiaki organization: RIKEN Center for Integrative Medical Science – sequence: 6 givenname: Matthew P. surname: Goetz fullname: Goetz, Matthew P. organization: Division of Medical Oncology, Mayo Clinic – sequence: 7 givenname: Richard M. surname: Weinshilboum fullname: Weinshilboum, Richard M. organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 8 givenname: Liewei surname: Wang fullname: Wang, Liewei email: wang.liewei@mayo.edu organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30944027$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuEzEUHaEi2gY-gA2yxKabgfFr7NkgVVVII1KQoiCxszyeO4mjiV1sT6V-Fj_CN-GQUtpKsLBs-Z5zfK7vOS2OnHdQFK9x9Q5jWb-PmFZclhVuSpyPJX1WnGBW85Iz8u3owfm4OI1xW1VYSC5fFMe0ahiriDgp3GoDaHBm-fkcXc2XpOLkcoYCrMdBJ4houvz5Aw1wA0NE2nVIB7_TSUdA1m1sa5MPGR1tTNoZQGkT_LjeoMXV6hNF7W2umTDaZN0aTWdL_LJ43ushwqu7fVJ8_ThdXVyWiy-z-cX5ojSc1qmUlSQgSDYLdcco1LpjArcGSIN7SWhercjdGSNEzSk3pJe8F8ZIyDAGdFLMD7qd11t1HexOh1vltVW_L3xYKx2SNQMoTnpCGZNMasM4ly3WrKG17LARWsu91oeD1vXY7qAz4FLQwyPRxxVnN2rtb1SdVQmTWeDsTiD47yPEpHY2GhgG7cCPURFSUUwbwkiGvn0C3foxuPxVGYUxE43Ik54Ubx46urfyZ6wZgA8AE3yMAfp7CK7UPjrqEB2Vo6P20VE0c8QTjrFJJ-v3Tdnhv0xyYMb8iltD-Gv636RfXV7WAg |
| CitedBy_id | crossref_primary_10_1002_cpt_2311 crossref_primary_10_1016_j_yexmp_2020_104480 crossref_primary_10_1002_mgg3_1299 crossref_primary_10_1002_wrna_1625 crossref_primary_10_1093_jnen_nlaa069 crossref_primary_10_1016_j_omtn_2021_08_005 crossref_primary_10_3390_jpm11060513 crossref_primary_10_1038_s41419_024_06814_3 crossref_primary_10_3390_ijms22084072 crossref_primary_10_1007_s12094_023_03189_3 crossref_primary_10_1111_ajco_13449 crossref_primary_10_1098_rsob_210218 crossref_primary_10_1016_j_prp_2024_155568 crossref_primary_10_3390_cancers13143530 crossref_primary_10_3390_ijms24021145 crossref_primary_10_1186_s12943_020_01181_x crossref_primary_10_3390_cancers12082162 crossref_primary_10_1007_s12325_021_01941_1 crossref_primary_10_1007_s00018_024_05480_0 crossref_primary_10_3390_cancers12061424 crossref_primary_10_1016_j_prp_2023_155084 crossref_primary_10_1038_s41598_025_86287_2 crossref_primary_10_1158_0008_5472_CAN_21_1155 crossref_primary_10_1038_s41419_020_02926_8 crossref_primary_10_1002_2211_5463_12964 crossref_primary_10_3390_cancers14092101 crossref_primary_10_3389_fendo_2022_839005 crossref_primary_10_2217_pgs_2019_0191 crossref_primary_10_3892_ol_2019_11093 crossref_primary_10_1002_ijc_70067 crossref_primary_10_1016_j_gpb_2023_01_006 |
| Cites_doi | 10.1038/nm.2351 10.1016/S0960-0760(02)00074-2 10.1158/1078-0432.CCR-07-0822 10.1200/JCO.2001.19.3.881 10.1038/onc.2012.343 10.1016/j.canlet.2015.12.026 10.1016/j.canlet.2018.06.039 10.1677/erc.1.01018 10.1016/S0093-7754(03)00302-6 10.1016/j.molcel.2011.08.018 10.1101/gad.1634608 10.1186/gb-2009-10-4-r41 10.1093/emboj/20.13.3484 10.1016/j.febslet.2012.10.040 10.1038/onc.2017.32 10.1158/0008-5472.CAN-05-4111 10.1016/j.cell.2013.06.020 10.1038/ng.2823 10.1128/MCB.18.4.1978 10.1677/erc.1.01023 10.1016/j.cellsig.2008.03.004 10.1007/s13205-018-1239-6 10.1016/j.celrep.2015.06.073 10.1038/sj.onc.1205420 10.1158/2159-8290.CD-13-0038 10.1038/ncb3467 10.1002/j.1460-2075.1993.tb05756.x 10.1097/00045391-200109000-00007 10.1038/nature11412 10.3322/caac.21349 10.1158/0008-5472.CAN-16-1371 10.1016/0092-8674(88)90485-0 10.1038/nrc721 10.1158/0008-5472.CAN-05-3984 10.1210/me.2002-0269 10.1126/science.271.5254.1427 10.1126/science.294.5548.1866 10.1038/nprot.2010.195 10.1126/science.270.5241.1491 10.1371/journal.pgen.1007031 10.1016/j.csbj.2014.07.005 10.1038/sj.onc.1206937 10.1677/erc.1.01257 10.1038/onc.2015.340 10.12659/MSM.900689 10.1073/pnas.95.14.8298 10.1172/JCI119337 10.1007/s12539-018-0302-7 10.1210/me.2004-0486 10.1038/s41388-018-0396-8 10.1038/onc.2008.461 10.1002/j.1460-2075.1996.tb00571.x 10.1146/annurev-biochem-051410-092902 10.1091/mbc.e03-11-0823 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13058-019-1130-3 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central (NC Live) ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1465-542X |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_52f2344848ac4558b1a49368d1c7aa8e PMC6448248 30944027 10_1186_s13058_019_1130_3 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P50 CA116201 – fundername: NCI NIH HHS grantid: U10 CA180863 – fundername: NCI NIH HHS grantid: R01 CA196648 |
| GroupedDBID | --- 04C 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACJQM ACMJI ACPRK ADBBV ADFRT ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BMSDO BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EIHBH EJD F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO ICW IHR INH INR ITC KQ8 O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RBZ ROL RPM RSV SBL SOJ TR2 U2A UKHRP WOQ AAYXX AFFHD CITATION ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c536t-8082e72858e6d43e6ad471bce291f823f82b7146cc776535c2f85f7cc8e71b4e3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 41 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000463749200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1465-542X 1465-5411 |
| IngestDate | Fri Oct 03 12:41:12 EDT 2025 Tue Nov 04 01:55:02 EST 2025 Thu Sep 04 18:45:38 EDT 2025 Sat Oct 11 13:41:44 EDT 2025 Thu Jan 02 22:58:33 EST 2025 Sat Nov 29 03:59:37 EST 2025 Tue Nov 18 21:33:46 EST 2025 Sat Sep 06 07:25:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | EGR1 Aromatase inhibitor ERα LMTK3 MIR2052HG PKC Lon noncoding RNA |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c536t-8082e72858e6d43e6ad471bce291f823f82b7146cc776535c2f85f7cc8e71b4e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/s13058-019-1130-3 |
| PMID | 30944027 |
| PQID | 2211479711 |
| PQPubID | 2034567 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_52f2344848ac4558b1a49368d1c7aa8e pubmedcentral_primary_oai_pubmedcentral_nih_gov_6448248 proquest_miscellaneous_2203139242 proquest_journals_2211479711 pubmed_primary_30944027 crossref_primary_10_1186_s13058_019_1130_3 crossref_citationtrail_10_1186_s13058_019_1130_3 springer_journals_10_1186_s13058_019_1130_3 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-04-03 |
| PublicationDateYYYYMMDD | 2019-04-03 |
| PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-03 day: 03 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Breast cancer research : BCR |
| PublicationTitleAbbrev | Breast Cancer Res |
| PublicationTitleAlternate | Breast Cancer Res |
| PublicationYear | 2019 |
| Publisher | BioMed Central Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: Springer Nature B.V – name: BMC |
| References | J Jiang (1130_CR27) 2007; 13 S Kato (1130_CR17) 1995; 270 S Ali (1130_CR15) 1993; 12 D Ezer (1130_CR58) 2014; 10 SF Yan (1130_CR54) 1998; 95 J Cairns (1130_CR41) 2017; 13 D Chen (1130_CR19) 2002; 21 1130_CR50 GE Weitsman (1130_CR20) 2006; 66 J Jacob (1130_CR44) 2016; 372 JL Rinn (1130_CR29) 2012; 81 WR Miller (1130_CR4) 2003; 30 I Ulitsky (1130_CR30) 2013; 154 PB Joel (1130_CR22) 1998; 18 RJ Santen (1130_CR14) 2005; 12 V Marsaud (1130_CR38) 2003; 17 C Wu (1130_CR32) 2016; 22 S Ali (1130_CR5) 2002; 2 SH Namekawa (1130_CR34) 2011; 6 Z Mou (1130_CR57) 2012; 586 J Stebbing (1130_CR26) 2013; 32 LF Macedo (1130_CR36) 2006; 66 VP Sukhatme (1130_CR51) 1988; 53 PE Goss (1130_CR3) 2001; 19 W Zhuo (1130_CR48) 2017; 19 G Giamas (1130_CR24) 2011; 17 Y Xu (1130_CR45) 2015; 12 RI Fernando (1130_CR37) 2004; 15 N Cancer Genome Atlas (1130_CR40) 2012; 490 JN Ingle (1130_CR42) 2013; 3 RW Brueggemeier (1130_CR7) 2001; 8 LA Martin (1130_CR13) 2005; 12 CA Lawson (1130_CR53) 1997; 99 DC Allred (1130_CR1) 1998; 11 M Zagurovskaya (1130_CR56) 2009; 28 SF Arnold (1130_CR18) 1994; 8 A Kubosaki (1130_CR55) 2009; 10 G Bunone (1130_CR21) 1996; 15 T Takizawa (1130_CR35) 2008; 22 1130_CR46 J Gu (1130_CR47) 2018; 434 BS Katzenellenbogen (1130_CR11) 1987; 47 JN Ingle (1130_CR28) 2016; 76 DR Robinson (1130_CR16) 2013; 45 KC Wang (1130_CR31) 2011; 43 X Xue (1130_CR33) 2016; 35 R Clarke (1130_CR6) 2003; 22 L Bjornstrom (1130_CR10) 2005; 19 K Belguise (1130_CR39) 2007; 117 LM Khachigian (1130_CR52) 1996; 271 A Chawla (1130_CR9) 2001; 294 CM Chan (1130_CR12) 2002; 81 DE Clark (1130_CR23) 2001; 20 V Thewes (1130_CR43) 2017; 36 KD Miller (1130_CR2) 2016; 66 B Kuske (1130_CR8) 2006; 13 K Anbarasu (1130_CR49) 2018; 8 S Park (1130_CR25) 2008; 20 |
| References_xml | – volume: 17 start-page: 715 issue: 6 year: 2011 ident: 1130_CR24 publication-title: Nat Med doi: 10.1038/nm.2351 – volume: 81 start-page: 333 issue: 4–5 year: 2002 ident: 1130_CR12 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/S0960-0760(02)00074-2 – volume: 8 start-page: 1208 issue: 9 year: 1994 ident: 1130_CR18 publication-title: Mol Endocrinol – volume: 13 start-page: 5769 issue: 19 year: 2007 ident: 1130_CR27 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0822 – volume: 117 start-page: 4009 issue: 12 year: 2007 ident: 1130_CR39 publication-title: J Clin Invest – volume: 19 start-page: 881 issue: 3 year: 2001 ident: 1130_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.3.881 – volume: 32 start-page: 3371 issue: 28 year: 2013 ident: 1130_CR26 publication-title: Oncogene doi: 10.1038/onc.2012.343 – volume: 372 start-page: 137 issue: 1 year: 2016 ident: 1130_CR44 publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.12.026 – volume: 434 start-page: 1 year: 2018 ident: 1130_CR47 publication-title: Cancer Lett doi: 10.1016/j.canlet.2018.06.039 – volume: 12 start-page: S61 issue: Suppl 1 year: 2005 ident: 1130_CR14 publication-title: Endocr Relat Cancer doi: 10.1677/erc.1.01018 – volume: 30 start-page: 3 issue: 4 Suppl 14 year: 2003 ident: 1130_CR4 publication-title: Semin Oncol doi: 10.1016/S0093-7754(03)00302-6 – volume: 43 start-page: 904 issue: 6 year: 2011 ident: 1130_CR31 publication-title: Mol Cell doi: 10.1016/j.molcel.2011.08.018 – volume: 22 start-page: 489 issue: 4 year: 2008 ident: 1130_CR35 publication-title: Genes Dev doi: 10.1101/gad.1634608 – volume: 10 start-page: R41 issue: 4 year: 2009 ident: 1130_CR55 publication-title: Genome Biol doi: 10.1186/gb-2009-10-4-r41 – volume: 20 start-page: 3484 issue: 13 year: 2001 ident: 1130_CR23 publication-title: EMBO J doi: 10.1093/emboj/20.13.3484 – volume: 586 start-page: 4319 issue: 24 year: 2012 ident: 1130_CR57 publication-title: FEBS Lett doi: 10.1016/j.febslet.2012.10.040 – volume: 36 start-page: 4124 issue: 29 year: 2017 ident: 1130_CR43 publication-title: Oncogene doi: 10.1038/onc.2017.32 – volume: 66 start-page: 10162 issue: 20 year: 2006 ident: 1130_CR20 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-4111 – volume: 154 start-page: 26 issue: 1 year: 2013 ident: 1130_CR30 publication-title: Cell doi: 10.1016/j.cell.2013.06.020 – volume: 45 start-page: 1446 issue: 12 year: 2013 ident: 1130_CR16 publication-title: Nat Genet doi: 10.1038/ng.2823 – volume: 18 start-page: 1978 issue: 4 year: 1998 ident: 1130_CR22 publication-title: Mol Cell Biol doi: 10.1128/MCB.18.4.1978 – volume: 12 start-page: S75 issue: Suppl 1 year: 2005 ident: 1130_CR13 publication-title: Endocr Relat Cancer doi: 10.1677/erc.1.01023 – volume: 20 start-page: 1368 issue: 7 year: 2008 ident: 1130_CR25 publication-title: Cell Signal doi: 10.1016/j.cellsig.2008.03.004 – volume: 8 start-page: 228 issue: 5 year: 2018 ident: 1130_CR49 publication-title: 3 Biotech doi: 10.1007/s13205-018-1239-6 – volume: 12 start-page: 837 issue: 5 year: 2015 ident: 1130_CR45 publication-title: Cell Rep doi: 10.1016/j.celrep.2015.06.073 – volume: 21 start-page: 4921 issue: 32 year: 2002 ident: 1130_CR19 publication-title: Oncogene doi: 10.1038/sj.onc.1205420 – volume: 3 start-page: 812 issue: 7 year: 2013 ident: 1130_CR42 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0038 – volume: 19 start-page: 81 issue: 2 year: 2017 ident: 1130_CR48 publication-title: Nat Cell Biol doi: 10.1038/ncb3467 – volume: 12 start-page: 1153 issue: 3 year: 1993 ident: 1130_CR15 publication-title: EMBO J doi: 10.1002/j.1460-2075.1993.tb05756.x – volume: 8 start-page: 333 issue: 5 year: 2001 ident: 1130_CR7 publication-title: Am J Ther doi: 10.1097/00045391-200109000-00007 – volume: 490 start-page: 61 issue: 7418 year: 2012 ident: 1130_CR40 publication-title: Nature doi: 10.1038/nature11412 – volume: 66 start-page: 271 issue: 4 year: 2016 ident: 1130_CR2 publication-title: CA Cancer J Clin doi: 10.3322/caac.21349 – volume: 76 start-page: 7012 issue: 23 year: 2016 ident: 1130_CR28 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-1371 – volume: 53 start-page: 37 issue: 1 year: 1988 ident: 1130_CR51 publication-title: Cell doi: 10.1016/0092-8674(88)90485-0 – volume: 2 start-page: 101 issue: 2 year: 2002 ident: 1130_CR5 publication-title: Nat Rev Cancer doi: 10.1038/nrc721 – volume: 66 start-page: 7775 issue: 15 year: 2006 ident: 1130_CR36 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3984 – volume: 17 start-page: 2013 issue: 10 year: 2003 ident: 1130_CR38 publication-title: Mol Endocrinol doi: 10.1210/me.2002-0269 – volume: 271 start-page: 1427 issue: 5254 year: 1996 ident: 1130_CR52 publication-title: Science doi: 10.1126/science.271.5254.1427 – volume: 294 start-page: 1866 issue: 5548 year: 2001 ident: 1130_CR9 publication-title: Science doi: 10.1126/science.294.5548.1866 – volume: 6 start-page: 270 issue: 3 year: 2011 ident: 1130_CR34 publication-title: Nat Protoc doi: 10.1038/nprot.2010.195 – volume: 270 start-page: 1491 issue: 5241 year: 1995 ident: 1130_CR17 publication-title: Science doi: 10.1126/science.270.5241.1491 – volume: 13 issue: 10 year: 2017 ident: 1130_CR41 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1007031 – volume: 10 start-page: 63 issue: 17 year: 2014 ident: 1130_CR58 publication-title: Comput Struct Biotechnol J doi: 10.1016/j.csbj.2014.07.005 – volume: 22 start-page: 7316 issue: 47 year: 2003 ident: 1130_CR6 publication-title: Oncogene doi: 10.1038/sj.onc.1206937 – volume: 13 start-page: 1121 issue: 4 year: 2006 ident: 1130_CR8 publication-title: Endocr Relat Cancer doi: 10.1677/erc.1.01257 – volume: 35 start-page: 2746 issue: 21 year: 2016 ident: 1130_CR33 publication-title: Oncogene doi: 10.1038/onc.2015.340 – volume: 22 start-page: 3860 year: 2016 ident: 1130_CR32 publication-title: Med Sci Monit doi: 10.12659/MSM.900689 – volume: 95 start-page: 8298 issue: 14 year: 1998 ident: 1130_CR54 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.95.14.8298 – volume: 47 start-page: 4355 issue: 16 year: 1987 ident: 1130_CR11 publication-title: Cancer Res – volume: 99 start-page: 1729 issue: 7 year: 1997 ident: 1130_CR53 publication-title: J Clin Invest doi: 10.1172/JCI119337 – ident: 1130_CR50 doi: 10.1007/s12539-018-0302-7 – volume: 19 start-page: 833 issue: 4 year: 2005 ident: 1130_CR10 publication-title: Mol Endocrinol doi: 10.1210/me.2004-0486 – ident: 1130_CR46 doi: 10.1038/s41388-018-0396-8 – volume: 28 start-page: 1121 issue: 8 year: 2009 ident: 1130_CR56 publication-title: Oncogene doi: 10.1038/onc.2008.461 – volume: 15 start-page: 2174 issue: 9 year: 1996 ident: 1130_CR21 publication-title: EMBO J doi: 10.1002/j.1460-2075.1996.tb00571.x – volume: 81 start-page: 145 year: 2012 ident: 1130_CR29 publication-title: Annu Rev Biochem doi: 10.1146/annurev-biochem-051410-092902 – volume: 15 start-page: 3266 issue: 7 year: 2004 ident: 1130_CR37 publication-title: Mol Biol Cell doi: 10.1091/mbc.e03-11-0823 – volume: 11 start-page: 155 issue: 2 year: 1998 ident: 1130_CR1 publication-title: Mod Pathol |
| SSID | ssj0017858 |
| Score | 2.449726 |
| Snippet | Background
Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA
MIR2052HG... Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated... Background Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG... Abstract Background Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 47 |
| SubjectTerms | AKT protein Androstenedione Aromatase Aromatase Inhibitors - pharmacology Binding sites Biomarkers Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Cell Line, Tumor Cell Proliferation Cell Survival - genetics Chromatin Drug Resistance, Neoplasm - genetics Early Growth Response Protein 1 - genetics Early Growth Response Protein 1 - metabolism EGR-1 protein EGR1 Endocrine therapy ERα ESR1 protein Estrogen Receptor alpha - genetics Estrogen Receptor alpha - metabolism Estrogens Extracellular signal-regulated kinase Female Fluorescence in situ hybridization FOXO3 protein Gene expression Genome-wide association studies Genomes Humans Immunoprecipitation Kinases Ligands LMTK3 Localization Lon noncoding RNA Lymphoblastoid cell lines Medical prognosis Membrane Proteins - genetics Membrane Proteins - metabolism MIR2052HG Models, Biological Oncology Phosphorylation PKC Polymorphism, Single Nucleotide Protein kinase C Protein Stability Protein-Serine-Threonine Kinases - genetics Protein-Serine-Threonine Kinases - metabolism Protein-tyrosine kinase Proteins Research Article Ribonucleic acid Ribosomal protein S6 kinase RNA RNA, Long Noncoding - genetics RNA-binding protein Signal Transduction Single-nucleotide polymorphism Surgical Oncology Transcription factors Transcription, Genetic Tumors Ubiquitin |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dixMxEA9yiPgieufHeqdEEB-U5Zpk8_VYpXcn2iLlhHsLm2yWW6ip7LYH92f5j_g3Ocluq_XzxYfC0mQhzPwmM7-dYQah50RXyktic1nZOjbVrnJrlci5rBmpxaiwuk7DJuRspi4u9IcfRn3FmrC-PXAvuGNOa8qAQxSqdAXnypKy0EyoijhZlsrH2xeing2ZGvIHUnE15DCJEscd3NQ8Fm3pnMBjzna8UGrW_7sI89dCyZ-ypckJndxFd4boEY_7U99DN3zYRwfjAMz50zV-gVM9Z_pQvo9uTYe0-QEKAAa8CG4-G-Pp2zkdcXp2itt-DL3v8GT-9QtexPKhDpehwmW7hEAW_BtuwmVjwehb2N3FUBMwgofZPvj99Pwdw_Ya1ly7bmIBNZ6czsl99PFkcv7mLB8GLeSOM7ECL6WolxRk5kVVMC_KCnyWdZ5qUivK4GclXKnOSSk4447WitfSuaTmwrMHaC8sg3-EsKaVh9VRVRNdaOF0WUvpeFkIxa2wVYZGG8EbN3Qhj8MwFiaxESVMrysDujJRV4Zl6OX2lc99C46_bX4dtbndGLtnpz8AU2bAlPkXpjJ0tMGCGUy6MxSociG1JCRDz7bLYIwxw1IGv1zHPbEVJlBamqGHPXS2J2FApIGsywzJHVDtHHV3JTSXqeF35NC0UBl6tYHf92P9URKP_4ckDtFtGq0mliqxI7S3atf-CbrprlZN1z5NNvcNHuAsvA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central (NC Live) dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5BihAXHi0PQ0GLhDiArGbf6xNKUdoiaFRFRerN8j5MIwWn2AlSfxZ_hN_E7GaTKjx64WDJ8oylteebmZ2d0QxCr0jhtFfE5MqZOjTVdrkxWuZC1YzUss9NUcdhE2o00mdnxUk6cOtSWeXKJkZD7WY2nJHvUYhUuCoUIe8uvuVhalTIrqYRGjfRVuhUxntoa384Ohmv8whKxwmdYA5ELjghKa9JtNzrwHqLUMhV5ARuc7bhmWID_7_tOv8snvwtgxod08G9__2k--hu2pLiwRJDD9AN32yjnUED4fjXS_waxyLRePq-jW4fp1z8DmoAYXja2PFogI8_jGlf0KND3C5n2_sOD8c_f-BpqEnqcNU4XLUz2B2D08ST5nxiwJK0wN2F_SsAD6eBQfjT8elHhs0l0Gy7mISqbDw8HJOH6PPB8PT9UZ6mN-RWMDkH16epVxQE4KXjzMvKgSM01tOC1JoyuIwCwVirlBRMWFprUStrI3a4Z49Qr5k1_gnCBXUeqH1Xg4wLaYuqVsqKikstjDQuQ_2V5EqbWpuHCRvTMoY4WpZLYZcg7DIIu2QZerN-5WLZ1-M65v0AhzVjaMkdH8zaL2XS8FLQmjIIdrmuLBdCG1LxgkntiFVVpX2GdlcoKJOd6MorCGTo5ZoMGh7SNlXjZ4vAE_prQpxMM_R4ib31ShhE57xPVYbUBio3lrpJaSbnsYt4CMwp1xl6u8Lv1bL--SeeXv8Rz9AdGhQqVDaxXdSbtwv_HN2y3-eTrn2RlPMXGqQ-gg priority: 102 providerName: ProQuest |
| Title | The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1 |
| URI | https://link.springer.com/article/10.1186/s13058-019-1130-3 https://www.ncbi.nlm.nih.gov/pubmed/30944027 https://www.proquest.com/docview/2211479711 https://www.proquest.com/docview/2203139242 https://pubmed.ncbi.nlm.nih.gov/PMC6448248 https://doaj.org/article/52f2344848ac4558b1a49368d1c7aa8e |
| Volume | 21 |
| WOSCitedRecordID | wos000463749200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: RBZ dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: DOA dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (NC Live) customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: RSV dateStart: 19991201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9NAEB-8OxFf_LjzI3qWFcQHJdjsZj_y2JPeB9pS4in1KWQ3G69QU0la4f4s_xH_Jmc3aaV6CvqQkGRnYZn8ZmYnM5kBeBYlhbIy0qEsdOmKaheh1kqEXJYsKkU_1knpm03I8VhNp8mk-4-7WWe7r0OSXlN7sVbiVYPalrvEqySM8DJkO7CH1k45aUzffdiEDqTiqgtfXjltywD5Ov1XbS5_z5H8JVDq7c_x7f9a-R241W03yaDFx124Zqt9OBhU6Gp_viTPiU8A9V_W9-HGqIuzH0CF6CHzyqTjARmdpbTP6ekJqdu-9bYhw_T7NzJ3-UYNyauC5PUCd75oEMmsuphp1BI1Ujdub4qgIl0zIPJ2dP6GEX2JY6ZezVzGNRmepNE9eH88PH99GnadGULDmViiWVPUSoqctqKImRV5gUZOG0uTqFSU4aEl6mBjpBSccUNLxUtpjMdFbNl92K0WlX0IJKGFxdF-UUZJnAiT5KWUhuexUFwLXQTQX7-uzHRly133jHnm3Rclspa9GbI3c-zNWAAvNlO-tDU7_kZ85DCwIXTltv2DRf0p66Q347SkDB3ZWOUm5lzpKI8TJlQRGZnnygZwuEZQ1umAJqPoW8cykVEUwNPNMEqvC8nklV2sHI2rnYk-MA3gQQu4zUoYet7o3csA5BYUt5a6PVLNLnyFcOd001gF8HINyJ_L-iMnHv0T9WO4SR2iXRITO4TdZb2yT-C6-bqcNXUPduRU-rPqwd7RcDxJe_5zB95NzkaTjz0vtD8At2A25g |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHQJeuGxcAgOMBDyAotW32H5AqEC3Vr2oqjppPIXEcbZKJR1JC-qfQuKP8Juw07RTuextDzxUqmqncpzvfD72OTkfwHOsEmkEjn2RxKkrqp34cSwDn4uU4jSos1ilpdiE6Pfl8bEabMH31bswLq1yxYklUSdT7c7I94ndqTChBMZvz774TjXKRVdXEhpLWHTM4pvdshVv2h_s831ByEFz9L7lV6oCvuY0mFlKlsQIIrk0QcKoCaLEEnSsDVE4lYTaTywsf2gtRMAp1ySVPBVal_fEDLX_ewW2mQW7rMH2oN0bfFzHLYQsFUHt5dznDOMqjoplsF_Y1YK7xDHlY_vVpxsrYSkY8Dcv989kzd8ituVCeHDrf5vC23CzcrlRY2kjd2DLZDuw28ii2fTzAr1EZRJsGV3YgWu9KtdgFzJrQWiS6WG_gXrtIalz0jpEuTlxgmemQM3hzx9o4nKuChRlCYryqfX-rVOAxtnpOLZMmdvehfPPrWGhShAJdXujDkXxwrbpfD52WeeoeTjEd-HoUibhHtSyaWYeAFIkMba1nqRYMRVoFaVCaB6xQPI4iBMP6iukhLoq3e4URCZhuYWTQbgEV2jBFTpwhdSDV-tLzpZ1Sy7q_M7Bb93RlRwvf5jmJ2HFYCEnKaF2M89kpBnnMsYRUzSQCdYiiqTxYG-FurDiwSI8h5wHz9bNlsFcWCrKzHTu-rj6ocr6ih7cX2J9PRJaV4zVifBAbFjBxlA3W7LxaVkl3R08ECY9eL2yl_Nh_XMmHl58E0_hemvU64bddr_zCG4QZ8wui4vuQW2Wz81juKq_zsZF_qQiBgSfLtuQfgGJ-Zqa |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtNAEB1BQRUvXFouhgKLhHgAWc3uei9-DJC0VduoCgX1zfJeTCMFp7ITpH4WP8I3MWs7QYGChHiwZHnG0np8dmePZzwD8JKmTntFTaycKUJRbRcbo2UsVMFpIXuJSYum2YQajfTZWXrS9Tmtl9nuy5Bk-09DqNJUzncvXNFOcS13a1x5RUjCSmOKpzG_DjeS0DMo0PUPn1ZhBKWF7kKZV9625oyamv1XbTR_z5f8JWja-KLhnf9-irtwu9uGkn6Lm3twzZdbsN0vkYJ_uSSvSJMY2nxx34LN4y7-vg0loopMSzse9cnxwZj1BNvfI1Xbz97XZDD-_o1MQx5STfLSkbya4Y4YHSWZlOcTg6tHhdp12LMi2EjXJIgcHZ8ecmIuUWarxSRkYpPB3pjeh4_Dwem7_bjr2BBbweUc3Z1mXjG0upcu4V7mDp2fsZ6ltNCM42EUrs3WKiUFF5YVWhTK2gYviecPYKOclf4RkJQ5j9KeK2iapNKmeaGUFXkitTDSuAh6y1eX2a6ceeiqMc0aWqNl1po3Q_NmwbwZj-D16paLtpbH35TfBjysFEMZ7ubCrPqcdbM6E6xgHAluonObCKENzZOUS-2oVXmufQQ7SzRl3dpQZww5d6JSRWkEL1ZinNUhVJOXfrYIOqGmJnJjFsHDFnyrkXBk5Mj6VQRqDZZrQ12XlJPzpnJ4IOMs0RG8WYLz57D-aInH_6T9HDZP3g-zo4PR4RO4xQK4Q54T34GNebXwT-Gm_Tqf1NWzZqb-ADvTPJ4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+lncRNA+MIR2052HG+regulates+ER%CE%B1+levels+and+aromatase+inhibitor+resistance+through+LMTK3+by+recruiting+EGR1&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Cairns%2C+Junmei&rft.au=Ingle%2C+James+N&rft.au=Kalari%2C+Krishna+R&rft.au=Shepherd%2C+Lois+E&rft.date=2019-04-03&rft.issn=1465-542X&rft.eissn=1465-542X&rft.volume=21&rft.issue=1&rft.spage=47&rft_id=info:doi/10.1186%2Fs13058-019-1130-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |